Therapeutic effect of aerosol form of aprotinin against Influenza


Cite item

Full Text

Abstract

There was studied the therapeutic efficacy ofinhalations ofaerosolform ofaprotinin delivered by a propellant in the metered-dose inhaler (MDI). This clinical trial was performed during the winter-spring outbreak caused with pandemic Influenza H1N1pdmO9. Aprotinin (a natural antiprotease low molecular weight polypeptide from bovine lungs) is known to be an antiviral drug, which inhibits influenza virus proteolytic activation accomplished by host respiratory proteases. Patients inhaled 2 aerosol doses of aprotinin (160 Kallikrein-inhibiting Units (KIU)) each 2 hours for 5 days. In comparison group, patients were treated with Ingavirin (a synthetic peptidoamine with unknown antiviral target), 90 mg per dayfor 5 days. On day 2 after treatment viral loads in naso-pharyngeal washes were determined. In aprotinin patients about the tenfold decrease of viral load was determined in comparison to Ingavirin patients. Duration of clinical symptoms, such as rhinorrhea, weakness, headache, sore throat, cough, chest pains, fever, in aprotinin group was 1 -2 days shorter then in Ingavirin group. No side effects neither patient discomfort were revealed in aprotinin group of patients. MDI, containing aprotinin as an active substance, can be recommended as a drug against Influenza caused by different viruses, including seasonal H1 N1, H3N2, swine-like H1 N1 pdmO9, and avian-like H7N9 viruses.

About the authors

O. P Zhirnov

D.I. Ivanovsky Institute of Virology

16, Gamalei Str., Moscow, Russian Federation, 123098

N. O Bokova

Moscow Infectious Clinics N1

63, Volokolamskoe Shosse, Moscow Russian Federation, 119419

E. I Isaeva

D.I. Ivanovsky Institute of Virology

16, Gamalei Str., Moscow, Russian Federation, 123098

I. V Vorobeva

D.I. Ivanovsky Institute of Virology

16, Gamalei Str., Moscow, Russian Federation, 123098

T. E Konakova

D.I. Ivanovsky Institute of Virology

16, Gamalei Str., Moscow, Russian Federation, 123098

N. A Malyshev

Moscow Infectious Clinics N1

63, Volokolamskoe Shosse, Moscow Russian Federation, 119419

References

  1. Das K. Antivirals targeting influenza A virus. J. Med. Chem. 2012; 55: 6263-77.
  2. Lee S.M., Yen H.L. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Antiviral Res. 2012; 96(3): 391-404.
  3. Жирнов О.П. Протеолитическая активация миксовирусов и новая стратегия в лечении вирусных заболеваний. Вопросы вирусологии. 1983; 4: 9-21.
  4. Жирнов О.П., Малышев Н.А. Апротинин, ингибитор протеаз, - новая альтернатива влечении гриппа. Российский медицинский журнал. 2012; 2: 52-6.
  5. Zhirnov O.P., Klenk H.D., Wright P.F. Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res. 2011; 92(1): 27-36.
  6. Жирнов О.П., Поярков С.В., Малышев Н.А. Мишени противовирусного и противовоспалительного действия апротинина: перспективы нового использования. Пульмонология. 2009; 33(3): 27-33.
  7. Zhirnov, О.P., Ikizler, М.R., Wright, P. Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell-associated and sensitive to exogenous antiproteases. J. Virol. 2002; 76: 8682-9.
  8. Zhimov О.Р, Matrosovich T.Y., Matrosovich M.N., Klenk H.D. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1 v influenza virus. Antiviral Chem. Chemother. 2011; 21: 169-74.
  9. Kido H., Okumura Y., Takahashi E. et al. Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure. Biochim. Biophys. Acta. 2012; 1824(1): 186-94.
  10. Bottcher-Friebertshauser E., Lu Y., Meyer D. et al. Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and В virus infections. Vaccine. 2012; 30(51):7374-80.
  11. Bertram S., Glowacka I., Steffen I. et al. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev Med Virol. 2010; 20(5): 298-310.
  12. Жирнов О.П., Киржнер Л.С., Овчаренко A.B., Малышев Н.А. Патогенетическая терапия острых респираторных заболеваний ингаляциями апротинина. Терапевтический архив. 1995; 6: 38-42.
  13. Жирнов О.П., Киржнер Л.С., Овчаренко А.В., Малышев Н.А. Клиническая эффективность аэрозоля апротинина при гриппе и парагриппе. Вестник РАМН. 1996; 5: 26-31.
  14. Zhirnov О.P., Kirzhner, L.S., Ovcharenko, А.V., Malyshev N.A. Aerosolized aprotinin is an effective drug against viral respiratory illness. Antiinfective Drug Chemother. 1996; 14: 209-16.
  15. Жирнов О.П., Сафонова Е.А., Овчаренко А.В., Малышев Н.А. Терапевтическая эффективность ингаляций апротинина у больных с острой респираторной вирусной инфекцией. Терапевтический архив. 2014. (в печати).
  16. Ovcharenko A.V., Zhirnov О.Р. Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice. Antiviral Res. 1994; 23: 107-18.
  17. Колобухина Л.В., Малышев Н.А., Меркулова Л.Н. и др. 2008. Изучение эффективности и безопасности нового противовирусного препарата Ингавирин при лечении больных гриппом. Русский медицинский журнал. 2008; 16(22): 1502-6.
  18. Колобухина Л.В., Меркулова Л.Н., Щелканов М.Ю. и др. 2009. Эффективность ингавирина в лечении гриппа у взрослых. Терапевтический архив. 2009; 81(3): 51-4.
  19. арубаев В.В., Слита А.В., Белявская С.В. и др. Противовирусная активность ингавирина на модели экспериментальной диссеминированной аденовирусной инфекции у животных. Вопросы вирусологии. 2011; 6: 23-7.
  20. арубаев В.В., Гаршинина А.В., Калинина Н.А. и др. Влияние ингавирина на ультраструктурные особенности морфогенеза парагриппозной инфекции in vitro и in vivo. Вопросы вирусологии. 2012; 5: 32-8.
  21. Planes С., Caughey G.H. Regulation of the epithelial Na+ channel by peptidases. Curr. Top. Dev. Biol. 2007; 78: 23-46.
  22. Coote K., Atherton-Watson H.C., Sugar R. et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J. Pharmacol. Exp. Ther. 2009; 329(2): 764-74.
  23. Nimishakavi S., Besprozvannaya M., Raymond W.W. et. al. Activity and inhibition of prostasin and matriptase on apical and basolateral surfaces of human airway epithelial cells. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2012; 303(2): L97-106.
  24. Li Q., Zhou L., Zhou M., Chen Z., Li F. et al. Preliminary Report: Epidemiology of the Avian Influenza A (H7N9) outbreak in China. N. Engl. J. Med. 2013. Apr 24 [Epub ahead of print] PubMed PMID: 23614499.
  25. Kageyama T., Fujisaki S., Takashita E. et. al. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill. 2013; 18(15).
  26. Lu S.H., Xi X.H., Zheng Y.F. et al. Analysis of the clinical characteristics and treatment of two patients with avian influenza virus (H7N9). Bioscf Trends. 2013; 7(2): 109-12.
  27. Beaulieu A., Gravel Ё., Cloutier A. et. al. Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium. J. Virol. 2013; 87(8): 4237-51.
  28. Bertram S., Glowacka I., Blazejewska P. et al. TMPRSS2 and MPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J. Virol. 2010; 84(19): 10016-25.
  29. Bottcher E., Matrosovich T., Beyerle M. et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 2006. 80(19): 9896-8.
  30. Bottcher-Friebertshauser E., Freuer C., Sielaff F. et al. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J. Virol. 2010; 84(11): 5605-14.
  31. Chaipan C., Kobasa D., Bertram S. et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 2009; 83(7): 3200-11.

Copyright (c) 2014 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies